Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | APP | P05067 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.54 |
| ▸ | PPARA | Q07869 | 4/20 | 0.54 |
| ▸ | PPARG | P37231 | 3/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26999155 | 1.00 | ATM (0.64) | ATMAPPCYP3A4PPARAPPARG | |
| SCHEMBL28406320 | 0.89 | ATM (0.62) | ATMAPPCYP3A4PPARAPPARG | |
| SCHEMBL23168417 | 0.89 | ATM (0.62) | ATMAPPCYP3A4PPARAPPARG | |
| SCHEMBL7279574 | 0.88 | ATM (0.68) | ATMAPPCYP3A4PPARAPPARG | |
| SCHEMBL6453827 | 0.88 | CTSK (0.54) | ATMAPPCYP3A4PPARAPPARG | |
| SCHEMBL7321063 | 0.85 | ATM (0.64) | ATMAPPCYP3A4PPARAPPARG | |
| SCHEMBL3682549 | 0.84 | ATM (0.70) | ATMAPPCYP3A4PPARAPPARG | |
| SCHEMBL3682545 | 0.84 | ATM (0.70) | ATMAPPCYP3A4PPARAPPARG | |
| SCHEMBL29471918 | 0.84 | ATM (0.70) | ATMAPPCYP3A4PPARAPPARG | |
| SCHEMBL15159951 | 0.84 | ATM (0.73) | ATMAPPCYP3A4PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198899-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-20140107120-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8637676-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637676-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2162442-B1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20080318951-A1 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080318951-A1 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. | 2008-12-25 | — | — | US | disclosed |
| WO-2008153857-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107120-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | ATM 4379/4885APP 2915/4885CYP3A4 642/4885 |
| US-20080318951-A1 | Dual-acting benzoimidazole antihypertensive agents | AGTR1, REN, AGTR2 | ATM 4379/4885APP 2915/4885CYP3A4 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.